Reviewers: Komal Arora, M.D., (see Reviewers page)
Revised: 22 March 2012, last major update March 2012
Copyright: (c) 2003-2012, PathologyOutlines.com, Inc.
● Also known as sarcomatoid carcinoma, metaplastic carcinoma, spindle-cell carcinoma, and malignant mixed mesodermal tumour
● Rare (<30 patients)
● May represent sarcomatoid transformation of prior adenocarcinoma or be related to radiotherapy or hormonal therapy
● Aggressive clinical course (Am J Surg Pathol 2006;30:1316)
● Biphasic tumor with adenocarcinoma and recognizable sarcoma components (chondrosarcoma, rhabdomyosarcoma, angiosarcoma, osteosarcoma, leiomyosarcoma)
● Epithelial component is cytokeratin+, PSA- and PAP+ (Am J Clin Pathol 1989;92:131)
● Sarcoma component negative for PSA, EMA, keratin
● Primary prostatic sarcoma, benign spindle cell proliferations such as inflammatory myofibroblastic tumor (pseudosarcomatous fibromyxoid tumor) and postoperative spindle cell nodule can be confused with the mesenchymal component of sarcomatoid carcinoma; note that in recurrent tumors, the mesenchymal component usually overgrows the epithelial component and so a pure sarcomatous pattern in the setting of pretreated adenocarcinoma should be assumed to represent sarcomatoid carcinoma
● Am J Surg Pathol 1993;17:342
End of Prostate > Other carcinomas > Carcinosarcoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).